ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 925

Cortical Reorganization after Duloxetine Treatment-Related Pain Decrease in Knee Osteoarthritis

Pascal Tetreault1, Marwan Baliki1, Etienne Vachon-Presseau1, Renita Evonne Yeasted2, Thomas J. Schnitzer3 and A. Vania Apkarian1,4, 1Physiology, Northwestern University, Chicago, IL, 2PM&R, Northwestern University, Chicago, IL, 3PM&R and Int Med, Northwestern University, Chicago, IL, 4Anaesthesia and Surgery, Northwestern University, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Knee, MRI, OA and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pain: Basic and Clinical Aspects I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Structural brain properties of patients coping with chronic painful conditions are becoming better understood but knowledge on how pain treatment affects these properties is still sparse. Assessment of cortical modifications during chronic pain evolution now permits identifying regions critically involved in painful pathologies. In this study, we evaluate structural brain reorganization of knee osteoarthritic (OA) patients after four months treatment with duloxetine (DLX) or placebo (P).

Methods: OA patients (n=40) meeting standard inclusion/exclusion criteria with pain ≥ 5 on 11 point NRS scale were randomized to DLX (60 mg) or placebo.  Pain measurements were made at week 0, 2, 3, 6 and 16 and anatomic MRI scans done at baseline and at end of treatment (week 16). The total gray matter volume of the brain was obtained using SIENAX tool from FSL and cortical gray matter density (GMD) changes were evaluated using a voxel based morphometry approach (FSL-VBM). To evaluate structural brain properties, longitudinal contrast was made by using a two-way repeated measure ANOVA design.

Results: Patients were categorized as responders (≥ 20% pain decrease from baseline) and nonresponders in both DLX and placebo groups. The total gray matter volume showed an interaction of time*treatment*response (F=16.69, p < 0.001). Following treatment, DLX responders had a borderline significant volume increase (p=0.07); in contrast, placebo responders had a significant volume decrease (p < 0.05). Whole-brain voxel-wise VBM contrast (before – after treatment) revealed that DLX-treated patients underwent modification in GMD in the left precentral gyrus, left middle frontal gyrus and bilateral ACC (figure 1A). Interestingly, when patients positively responded to their treatment, independent of compound received, difference in GMD was observed only in the left precentral gyrus (figure 1B). In addition, regions in the left middle frontopolar (figure 1C) and inferior temporal gyri showed GMD changes when DLX induced pain relief. We thus show that some cortical regions presenting GMD reorganization were shared among all 4 groups studied, suggesting that a proportion of gray matter structural modification may be naturally occurring in time while other regional changes are directly related to treatment received.

Conclusion: Understanding how pharmacological treatment affects structural brain properties is important to assess drug efficacy and its potential deleterious effects. We herein show that pharmacological treatment of OA pain is affecting cortical reorganization in a way that is dependent on treatment, response and the interaction of both.


Disclosure:

P. Tetreault,
None;

M. Baliki,
None;

E. Vachon-Presseau,
None;

R. E. Yeasted,
None;

T. J. Schnitzer,
None;

A. V. Apkarian,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cortical-reorganization-after-duloxetine-treatment-related-pain-decrease-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology